---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040465"
form_type: "8-K"
ticker: "IBO"
cik: "0001834105"
company_name: "IMPACT BIOMEDICAL INC."
filed_at: "2024-10-08T23:59:59+00:00"
generated_at: "2026-05-30T18:15:09.377568+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Impact Biomedical enters three-year CEO employment agreement with Frank Heuszel

## Summary
- Term from Oct 3, 2024 to Oct 3, 2027; base salary $200K year 1, $250K years 2 and 3.
- Mandatory bonus: $150K year 1, $100K each year 2 and 3; discretionary bonuses eligible.
- Option grant of 300,000 shares at $3.00/share under 2023 Equity Incentive Plan.
- Agreement defines termination for cause and good reason; executive remains CEO, Chairman, President.

## SEC filing metadata
- accession: 0001493152-24-040465
- form_type: 8-K
- ticker: IBO
- cik: 0001834105
- company_name: IMPACT BIOMEDICAL INC.
- filed_at: 2024-10-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1834105/000149315224040465/0001493152-24-040465-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1834105/000149315224040465/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040465
- JSON: https://secwatch.observer/filing/0001493152-24-040465.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040465.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.